{
    "abstract": "Introduction Multiple vaccination visits and administrations can be stressful for infants, parents and healthcare providers. Multivalent combination vaccines can deliver the required number of antigens in fewer injections and clinic visits, while vaccine co-administration can also reduce the number of visits. This non-inferiority study was undertaken to evaluate the feasibility of co-administering a combined measles-mumps-rubella-varicella (MMRV) vaccine with conjugated meningococcal C (MenC) vaccine in a large cohort of healthy Italian toddlers. Methods Healthy subjects aged 13\u201315\u00a0months were randomized (2:1:1) to receive single doses of either: co-administered MMRV\u00a0+\u00a0MenC at the same visit (MMRV\u00a0+\u00a0MenC group); or MMRV followed 42\u00a0days later by MenC (MMRV group); or MenC followed 42\u00a0days later by MMRV (MenC group). Blood samples were collected before and 43\u00a0days after vaccination. Antibody titers against MMRV were measured using ELISA. Functional-anti-meningococcal-serogroup activity (rSBAMenC) was assessed using a serum bactericidal test. Solicited local and general reactions were recorded for up to 4 and 42\u00a0days post-vaccination, respectively. Non-inferiority of MMRV\u00a0+\u00a0MenC to MMRV (post-dose-1 seroconversion rates) and MMRV\u00a0+\u00a0MenC to MenC (post-dose-1 seroprotection rates) was achieved if the lower limit (LL) of the 95% confidence interval (CI) for the group difference was \u2a7e\u221210% for each antigen. Results 716 subjects were enrolled in the study. At 42\u00a0days post-vaccination, the MMRV seroconversion rates were 99.3% (measles), 94.5% (mumps), 100% (rubella) and 99.7% (varicella) in the MMRV\u00a0+\u00a0MenC group, and 99.4%, 93.2%, 100% and 100%, respectively, in the MMRV group. The seroprotection rates against rSBA-MenC were 98.3% in the MMRV\u00a0+\u00a0MenC group and 99.3% in the MenC group. Non-inferiority was reached for all the vaccine antigens. The safety profiles were as expected for these vaccines. Conclusion The immune responses elicited by co-administered MMRV\u00a0+\u00a0MenC were non-inferior to those elicited by MMRV or MenC alone and support vaccination of children with both vaccines at a single visit. Clinical Trials registration: NCT01506193.",
    "author_highlights": [
        {
            "endOffset": 12191,
            "sentence": "Open, randomized, phase IIIb study conducted at 13 centers in Italy.",
            "startOffset": 12123
        },
        {
            "endOffset": 12277,
            "sentence": "MMRV + MenC vaccine seroconversion rates non-inferior to separate MMRV/MenC vaccines.",
            "startOffset": 12192
        },
        {
            "endOffset": 12359,
            "sentence": "MenC vaccine did not alter the safety profile of MMRV vaccine administered alone.",
            "startOffset": 12278
        },
        {
            "endOffset": 12436,
            "sentence": "Co-administered MMRV and MenC vaccines could reduce number of clinic visits.",
            "startOffset": 12360
        }
    ],
    "bib_entries": {
        "b0005": null,
        "b0010": null,
        "b0015": {
            "authors": [
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Filia"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Bella"
                },
                {
                    "first": "M. C.",
                    "initial": "M.C.",
                    "last": "Rota"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Tavilla"
                },
                {
                    "first": "F.",
                    "initial": "F.",
                    "last": "Magurano"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Baggieri"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Nicoletti"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Iannazzo"
                },
                {
                    "first": "M. G.",
                    "initial": "M.G.",
                    "last": "Pompa"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Declich"
                }
            ],
            "issn": "1025496X",
            "pmid": "23725868",
            "pub_year": 2013,
            "title": "Analysis of national measles surveillance data in Italy from October 2010 to December 2011 and priorities for reaching the 2015 measles elimination goal",
            "volume": "18"
        },
        "b0020": {
            "authors": [
                {
                    "first": "Paolo",
                    "initial": "P.",
                    "last": "Bonanni"
                },
                {
                    "first": "Antonio",
                    "initial": "A.",
                    "last": "Ferro"
                },
                {
                    "first": "Raniero",
                    "initial": "R.",
                    "last": "Guerra"
                },
                {
                    "first": "Stefania",
                    "initial": "S.",
                    "last": "Iannazzo"
                },
                {
                    "first": "Anna",
                    "initial": "A.",
                    "last": "Odone"
                },
                {
                    "first": "Maria Grazia",
                    "initial": "M.G.",
                    "last": "Pompa"
                },
                {
                    "first": "Elvira",
                    "initial": "E.",
                    "last": "Rizzuto"
                },
                {
                    "first": "Carlo",
                    "initial": "C.",
                    "last": "Signorelli"
                }
            ],
            "firstpage": "146",
            "issn": "11209763",
            "lastpage": "158",
            "pmid": "26499433",
            "pub_year": 2015,
            "title": "Vaccine coverage in Italy and assessment of the 2012-2014 National Immunization Prevention Plan",
            "volume": "39"
        },
        "b0025": null,
        "b0030": null,
        "b0035": null,
        "b0040": {
            "authors": [
                {
                    "first": "Paolo",
                    "initial": "P.",
                    "last": "Bonanni"
                },
                {
                    "first": "Chiara",
                    "initial": "C.",
                    "last": "Azzari"
                },
                {
                    "first": "Paolo",
                    "initial": "P.",
                    "last": "Castiglia"
                },
                {
                    "first": "Giampietro",
                    "initial": "G.",
                    "last": "Chiamenti"
                },
                {
                    "first": "Giorgio",
                    "initial": "G.",
                    "last": "Conforti"
                },
                {
                    "first": "Michele",
                    "initial": "M.",
                    "last": "Conversano"
                },
                {
                    "first": "Giovanni",
                    "initial": "G.",
                    "last": "Corsello"
                },
                {
                    "first": "Giuseppe",
                    "initial": "G.",
                    "last": "Ferrera"
                },
                {
                    "first": "Antonio",
                    "initial": "A.",
                    "last": "Ferro"
                },
                {
                    "first": "Giancarlo",
                    "initial": "G.",
                    "last": "Icardi"
                },
                {
                    "first": "Pasquale G.iuseppe",
                    "initial": "P.G.i.",
                    "last": "Macr\u00ec"
                },
                {
                    "first": "Tommaso",
                    "initial": "T.",
                    "last": "Maio"
                },
                {
                    "first": "Walter",
                    "initial": "W.",
                    "last": "Ricciardi"
                },
                {
                    "first": "Rocco",
                    "initial": "R.",
                    "last": "Russo"
                },
                {
                    "first": "Silvestro",
                    "initial": "S.",
                    "last": "Scotti"
                },
                {
                    "first": "Carlo",
                    "initial": "C.",
                    "last": "Signorelli"
                },
                {
                    "first": "Luigi",
                    "initial": "L.",
                    "last": "Sudano"
                },
                {
                    "first": "Alberto G.iovanni",
                    "initial": "A.G.i.",
                    "last": "Ugazio"
                },
                {
                    "first": "Alberto",
                    "initial": "A.",
                    "last": "Villani"
                },
                {
                    "first": "Giovanni",
                    "initial": "G.",
                    "last": "Vitali Rosati"
                }
            ],
            "firstpage": "131",
            "issn": "11209763",
            "lastpage": "146",
            "pmid": "25759359",
            "pub_year": 2014,
            "title": "The 2014 lifetime immunization schedule approved by the Italian scientific societies. Italian Society of Hygiene, Preventive Medicine, and Public Health. Italian Society of Pediatrics. Italian Federation of Pediatric Physicians. Italian Federation of General Medical Physicians. Arezzo Service of Legal Medicine",
            "volume": "38"
        },
        "b0045": {
            "authors": [
                {
                    "first": "Timo",
                    "initial": "T.",
                    "last": "Vesikari"
                },
                {
                    "first": "Aino",
                    "initial": "A.",
                    "last": "Karvonen"
                },
                {
                    "first": "Veronique",
                    "initial": "V.",
                    "last": "Bianco"
                },
                {
                    "first": "Marie",
                    "initial": "M.",
                    "last": "Van der Wielen"
                },
                {
                    "first": "Jacqueline",
                    "initial": "J.",
                    "last": "Miller"
                }
            ],
            "doi": "10.1016/j.vaccine.2011.03.043",
            "firstpage": "4274",
            "issn": "0264410X",
            "lastpage": "4284",
            "pmid": "21443965",
            "pub_year": 2011,
            "title": "Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: An open, randomized controlled trial",
            "volume": "29"
        },
        "b0050": {
            "authors": [
                {
                    "first": "Nicola P.",
                    "initial": "N.P.",
                    "last": "Klein"
                },
                {
                    "first": "Julie",
                    "initial": "J.",
                    "last": "Shepard"
                },
                {
                    "first": "Lisa",
                    "initial": "L.",
                    "last": "Bedell"
                },
                {
                    "first": "Tatjana",
                    "initial": "T.",
                    "last": "Odrljin"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Dull"
                }
            ],
            "doi": "10.1016/j.vaccine.2012.03.080",
            "firstpage": "3929",
            "issn": "0264410X",
            "lastpage": "3936",
            "pmid": "22504039",
            "pub_year": 2012,
            "title": "Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine administered concomitantly with measles, mumps, rubella, varicella vaccine in healthy toddlers",
            "volume": "30"
        },
        "b0055": {
            "authors": [
                {
                    "first": "Giuseppe",
                    "initial": "G.",
                    "last": "Ferrera"
                },
                {
                    "first": "Mario",
                    "initial": "M.",
                    "last": "Cuccia"
                },
                {
                    "first": "Gabriele",
                    "initial": "G.",
                    "last": "Mereu"
                },
                {
                    "first": "Giancarlo",
                    "initial": "G.",
                    "last": "Icardi"
                },
                {
                    "first": "Gianni",
                    "initial": "G.",
                    "last": "Bona"
                },
                {
                    "first": "Susanna",
                    "initial": "S.",
                    "last": "Esposito"
                },
                {
                    "first": "Federico",
                    "initial": "F.",
                    "last": "Marchetti"
                },
                {
                    "first": "Marc",
                    "initial": "M.",
                    "last": "Messier"
                },
                {
                    "first": "Sherine",
                    "initial": "S.",
                    "last": "Kuriyakose"
                },
                {
                    "first": "Karin",
                    "initial": "K.",
                    "last": "Hardt"
                }
            ],
            "doi": "10.4161/hv.8.3.18650",
            "firstpage": "345",
            "issn": "2164554X",
            "lastpage": "352",
            "pmid": "22327497",
            "pub_year": 2012,
            "title": "Booster vaccination of pre-school children with reduced-antigen-content diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine co-administered with measles-mumps-rubella-varicella vaccine: A randomized, controlled trial in children primed according to a 2+1 schedule in infancy",
            "volume": "8"
        },
        "b0060": {
            "authors": [
                {
                    "first": "Timo",
                    "initial": "T.",
                    "last": "Vesikari"
                },
                {
                    "first": "Aino",
                    "initial": "A.",
                    "last": "Karvonen"
                },
                {
                    "first": "Niklas",
                    "initial": "N.",
                    "last": "Lindblad"
                },
                {
                    "first": "Tiina",
                    "initial": "T.",
                    "last": "Korhonen"
                },
                {
                    "first": "Patricia",
                    "initial": "P.",
                    "last": "Lommel"
                },
                {
                    "first": "Paul",
                    "initial": "P.",
                    "last": "Willems"
                },
                {
                    "first": "Ilse",
                    "initial": "I.",
                    "last": "Dieussaert"
                },
                {
                    "first": "Lode",
                    "initial": "L.",
                    "last": "Schuerman"
                }
            ],
            "doi": "10.1097/INF.0b013e3181dffabf",
            "firstpage": "e47",
            "issn": "08913668",
            "lastpage": "e56",
            "pmid": "20508478",
            "pub_year": 2010,
            "title": "Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable haemophilus influenzae protein D conjugate vaccine coadministered with measles-mumps-rubella-varicella vaccine in children aged 12 to 16 months",
            "volume": "29"
        },
        "b0065": {
            "authors": [
                {
                    "first": "Timo",
                    "initial": "T.",
                    "last": "Vesikari"
                },
                {
                    "first": "Susanna",
                    "initial": "S.",
                    "last": "Esposito"
                },
                {
                    "first": "Roman",
                    "initial": "R.",
                    "last": "Prymula"
                },
                {
                    "first": "Ellen",
                    "initial": "E.",
                    "last": "Ypma"
                },
                {
                    "first": "Igor",
                    "initial": "I.",
                    "last": "Kohl"
                },
                {
                    "first": "Daniela",
                    "initial": "D.",
                    "last": "Toneatto"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Dull"
                },
                {
                    "first": "Alan",
                    "initial": "A.",
                    "last": "Kimura"
                }
            ],
            "doi": "10.1016/S0140-6736(12)61961-8",
            "firstpage": "825",
            "issn": "01406736",
            "lastpage": "835",
            "pmid": "23324563",
            "pub_year": 2013,
            "title": "Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: Results of two randomised trials",
            "volume": "381"
        },
        "b0070": {
            "authors": [
                {
                    "first": "Henry",
                    "initial": "H.",
                    "last": "Shinefield"
                },
                {
                    "first": "Steve",
                    "initial": "S.",
                    "last": "Black"
                },
                {
                    "first": "Marci",
                    "initial": "M.",
                    "last": "Thear"
                },
                {
                    "first": "Daniel",
                    "initial": "D.",
                    "last": "Coury"
                },
                {
                    "first": "Keith",
                    "initial": "K.",
                    "last": "Reisinger"
                },
                {
                    "first": "Edward",
                    "initial": "E.",
                    "last": "Rothstein"
                },
                {
                    "first": "Jin",
                    "initial": "J.",
                    "last": "Xu"
                },
                {
                    "first": "Jonathan",
                    "initial": "J.",
                    "last": "Hartzel"
                },
                {
                    "first": "Barbara",
                    "initial": "B.",
                    "last": "Evans"
                },
                {
                    "first": "Laura",
                    "initial": "L.",
                    "last": "Digilio"
                },
                {
                    "first": "Florian",
                    "initial": "F.",
                    "last": "Sch\u00e4del"
                },
                {
                    "first": "Michelle L.Huffman",
                    "initial": "M.L.H.",
                    "last": "Brown"
                },
                {
                    "first": "Barbara",
                    "initial": "B.",
                    "last": "Kuter"
                }
            ],
            "doi": "10.1097/01.inf.0000207857.10947.1f",
            "firstpage": "287",
            "issn": "08913668",
            "lastpage": "292",
            "pmid": "16567978",
            "pub_year": 2006,
            "title": "Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined Haemophilus influenzae type b conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines",
            "volume": "25"
        },
        "b0075": {
            "authors": [
                {
                    "first": "Henry",
                    "initial": "H.",
                    "last": "Shinefield"
                },
                {
                    "first": "Steve",
                    "initial": "S.",
                    "last": "Black"
                },
                {
                    "first": "Laura",
                    "initial": "L.",
                    "last": "Digilio"
                },
                {
                    "first": "Keith",
                    "initial": "K.",
                    "last": "Reisinger"
                },
                {
                    "first": "Mark",
                    "initial": "M.",
                    "last": "Blatter"
                },
                {
                    "first": "Jacqueline O.",
                    "initial": "J.O.",
                    "last": "Gress"
                },
                {
                    "first": "Michelle L.",
                    "initial": "M.L.",
                    "last": "Hoffman Brown"
                },
                {
                    "first": "Karen A.",
                    "initial": "K.A.",
                    "last": "Eves"
                },
                {
                    "first": "Stephanie Olsen",
                    "initial": "S.O.",
                    "last": "Klopfer"
                },
                {
                    "first": "Florian",
                    "initial": "F.",
                    "last": "Sch\u00e4del"
                },
                {
                    "first": "Barbara J.",
                    "initial": "B.J.",
                    "last": "Kuter"
                }
            ],
            "doi": "10.1097/01.inf.0000172902.25009.a1",
            "firstpage": "665",
            "issn": "08913668",
            "lastpage": "669",
            "pmid": "16094217",
            "pub_year": 2005,
            "title": "Evaluation of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children",
            "volume": "24"
        },
        "b0080": {
            "authors": [
                {
                    "first": "Volker",
                    "initial": "V.",
                    "last": "Schuster"
                },
                {
                    "first": "Walter",
                    "initial": "W.",
                    "last": "Otto"
                },
                {
                    "first": "Lothar",
                    "initial": "L.",
                    "last": "Maurer"
                },
                {
                    "first": "Patricia",
                    "initial": "P.",
                    "last": "Tcherepnine"
                },
                {
                    "first": "Ulrich",
                    "initial": "U.",
                    "last": "Pfletschinger"
                },
                {
                    "first": "Klaus",
                    "initial": "K.",
                    "last": "Kindler"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Soemantri"
                },
                {
                    "first": "Uta",
                    "initial": "U.",
                    "last": "Walther"
                },
                {
                    "first": "Ute",
                    "initial": "U.",
                    "last": "MacHoldt"
                },
                {
                    "first": "Martine",
                    "initial": "M.",
                    "last": "Douha"
                },
                {
                    "first": "Patrice",
                    "initial": "P.",
                    "last": "Pierson"
                },
                {
                    "first": "Paul",
                    "initial": "P.",
                    "last": "Willems"
                }
            ],
            "doi": "10.1097/INF.0b013e318170bb22",
            "firstpage": "724",
            "issn": "08913668",
            "lastpage": "730",
            "pmid": "18600190",
            "pub_year": 2008,
            "title": "Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life",
            "volume": "27"
        },
        "b0085": {
            "authors": [
                {
                    "first": "Markus",
                    "initial": "M.",
                    "last": "Knuf"
                },
                {
                    "first": "Pirmin",
                    "initial": "P.",
                    "last": "Habermehl"
                },
                {
                    "first": "Fred",
                    "initial": "F.",
                    "last": "Zepp"
                },
                {
                    "first": "Wilma",
                    "initial": "W.",
                    "last": "Mannhardt"
                },
                {
                    "first": "Martin",
                    "initial": "M.",
                    "last": "Kuttnig"
                },
                {
                    "first": "Pekka",
                    "initial": "P.",
                    "last": "Muttonen"
                },
                {
                    "first": "Albrecht",
                    "initial": "A.",
                    "last": "Prieler"
                },
                {
                    "first": "Hartwig",
                    "initial": "H.",
                    "last": "Maurer"
                },
                {
                    "first": "Helmtrud",
                    "initial": "H.",
                    "last": "Bisanz"
                },
                {
                    "first": "Nadia",
                    "initial": "N.",
                    "last": "Tornieporth"
                },
                {
                    "first": "Dominique",
                    "initial": "D.",
                    "last": "Descamps"
                },
                {
                    "first": "Paul",
                    "initial": "P.",
                    "last": "Willems"
                }
            ],
            "doi": "10.1097/01.inf.0000195626.35239.58",
            "firstpage": "12",
            "issn": "08913668",
            "lastpage": "18",
            "pmid": "16395096",
            "pub_year": 2006,
            "title": "Immunogenicity and safety of two doses of tetravalent measles-mumps- rubella-varicella vaccine in healthy children",
            "volume": "25"
        },
        "b0090": {
            "authors": [
                {
                    "first": "Tania",
                    "initial": "T.",
                    "last": "Schink"
                },
                {
                    "first": "Jakob",
                    "initial": "J.",
                    "last": "Holstiege"
                },
                {
                    "first": "Frank",
                    "initial": "F.",
                    "last": "Kowalzik"
                },
                {
                    "first": "Fred",
                    "initial": "F.",
                    "last": "Zepp"
                },
                {
                    "first": "Edeltraut",
                    "initial": "E.",
                    "last": "Garbe"
                }
            ],
            "doi": "10.1016/j.vaccine.2013.12.011",
            "firstpage": "645",
            "issn": "0264410X",
            "lastpage": "650",
            "pmid": "24374498",
            "pub_year": 2014,
            "title": "Risk of febrile convulsions after MMRV vaccination in comparison to MMR or MMR+V vaccination",
            "volume": "32"
        },
        "b0095": {
            "authors": [
                {
                    "first": "Steven J.",
                    "initial": "S.J.",
                    "last": "Jacobsen"
                },
                {
                    "first": "Bradley K.",
                    "initial": "B.K.",
                    "last": "Ackerson"
                },
                {
                    "first": "Lina S.",
                    "initial": "L.S.",
                    "last": "Sy"
                },
                {
                    "first": "Trung N.",
                    "initial": "T.N.",
                    "last": "Tran"
                },
                {
                    "first": "Tonia L.",
                    "initial": "T.L.",
                    "last": "Jones"
                },
                {
                    "first": "Janis F.",
                    "initial": "J.F.",
                    "last": "Yao"
                },
                {
                    "first": "Fagen",
                    "initial": "F.",
                    "last": "Xie"
                },
                {
                    "first": "T.",
                    "initial": "T.",
                    "last": "Craig Cheetham"
                },
                {
                    "first": "Patricia",
                    "initial": "P.",
                    "last": "Saddier"
                }
            ],
            "doi": "10.1016/j.vaccine.2009.05.056",
            "firstpage": "4656",
            "issn": "0264410X",
            "lastpage": "4661",
            "pmid": "19520201",
            "pub_year": 2009,
            "title": "Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting",
            "volume": "27"
        },
        "b0100": {
            "authors": [
                {
                    "first": "Nicola P.",
                    "initial": "N.P.",
                    "last": "Klein"
                },
                {
                    "first": "Bruce",
                    "initial": "B.",
                    "last": "Fireman"
                },
                {
                    "first": "W. Katherine",
                    "initial": "W.K.",
                    "last": "Yih"
                },
                {
                    "first": "Edwin",
                    "initial": "E.",
                    "last": "Lewis"
                },
                {
                    "first": "Martin",
                    "initial": "M.",
                    "last": "Kulldorff"
                },
                {
                    "first": "Paula",
                    "initial": "P.",
                    "last": "Ray"
                },
                {
                    "first": "Roger",
                    "initial": "R.",
                    "last": "Baxter"
                },
                {
                    "first": "Simon",
                    "initial": "S.",
                    "last": "Hambidge"
                },
                {
                    "first": "James",
                    "initial": "J.",
                    "last": "Nordin"
                },
                {
                    "first": "Allison",
                    "initial": "A.",
                    "last": "Naleway"
                },
                {
                    "first": "Edward A.",
                    "initial": "E.A.",
                    "last": "Belongia"
                },
                {
                    "first": "Tracy",
                    "initial": "T.",
                    "last": "Lieu"
                },
                {
                    "first": "James",
                    "initial": "J.",
                    "last": "Baggs"
                },
                {
                    "first": "Eric",
                    "initial": "E.",
                    "last": "Weintraub"
                }
            ],
            "doi": "10.1542/peds.2010-0665",
            "firstpage": "e1",
            "issn": "00314005",
            "lastpage": "e8",
            "pmid": "20587679",
            "pub_year": 2010,
            "title": "Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures",
            "volume": "126"
        },
        "b0105": null,
        "b0110": {
            "authors": [
                {
                    "first": "Silvia",
                    "initial": "S.",
                    "last": "Cocchio"
                },
                {
                    "first": "Giovanna",
                    "initial": "G.",
                    "last": "Zanoni"
                },
                {
                    "first": "Roberta",
                    "initial": "R.",
                    "last": "Opri"
                },
                {
                    "first": "Francesca",
                    "initial": "F.",
                    "last": "Russo"
                },
                {
                    "first": "Vincenzo",
                    "initial": "V.",
                    "last": "Baldo"
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                },
                {
                    "first": "Tatjana",
                    "initial": "T.",
                    "last": "Baldovin"
                },
                {
                    "first": "Patrizia",
                    "initial": "P.",
                    "last": "Furlan"
                },
                {
                    "first": "Francesca",
                    "initial": "F.",
                    "last": "Fontebasso"
                },
                {
                    "first": "Erica",
                    "initial": "E.",
                    "last": "Bicciato"
                },
                {
                    "first": "Gaetano",
                    "initial": "G.",
                    "last": "Morgillo"
                },
                {
                    "first": "Veronica",
                    "initial": "V.",
                    "last": "Minascurta"
                },
                {
                    "first": "Gisella",
                    "initial": "G.",
                    "last": "Pitter"
                },
                {
                    "first": "Tea",
                    "initial": "T.",
                    "last": "Burmaz"
                },
                {
                    "first": "Paola",
                    "initial": "P.",
                    "last": "Anello"
                },
                {
                    "first": "Roberta",
                    "initial": "R.",
                    "last": "Opri"
                },
                {
                    "first": "Ugo",
                    "initial": "U.",
                    "last": "Moretti"
                },
                {
                    "first": "Laura Augusta",
                    "initial": "L.A.",
                    "last": "Gonella"
                },
                {
                    "first": "Anna Ferraresso e.",
                    "initial": "A.F.e.",
                    "last": "Antonio Ferro"
                },
                {
                    "first": "Maria Domenica",
                    "initial": "M.D.",
                    "last": "Pedone"
                },
                {
                    "first": "Vittorio",
                    "initial": "V.",
                    "last": "Selle"
                },
                {
                    "first": "Maurizio Sforzi e.",
                    "initial": "M.S.e.",
                    "last": "Emanuela Destefani"
                },
                {
                    "first": "Anna",
                    "initial": "A.",
                    "last": "Pupo"
                },
                {
                    "first": "Sandra",
                    "initial": "S.",
                    "last": "Costa"
                },
                {
                    "first": "Vittorina Fassinato e.",
                    "initial": "V.F.e.",
                    "last": "Viviana Vitale"
                },
                {
                    "first": "Giuseppina Napoletano e.",
                    "initial": "G.N.e.",
                    "last": "Giambattista Zivelonghi"
                }
            ],
            "doi": "10.1080/21645515.2015.1101198",
            "firstpage": "651",
            "issn": "21645515",
            "lastpage": "654",
            "pmid": "26528829",
            "pub_year": 2016,
            "title": "A postmarket safety comparison of 2 vaccination strategies for measles, mumps, rubella and varicella in Italy",
            "volume": "12"
        },
        "b0115": {
            "authors": [
                {
                    "first": "Hanna",
                    "initial": "H.",
                    "last": "Czajka"
                },
                {
                    "first": "Volker",
                    "initial": "V.",
                    "last": "Schuster"
                },
                {
                    "first": "Fred",
                    "initial": "F.",
                    "last": "Zepp"
                },
                {
                    "first": "Susanna",
                    "initial": "S.",
                    "last": "Esposito"
                },
                {
                    "first": "Martine",
                    "initial": "M.",
                    "last": "Douha"
                },
                {
                    "first": "Paul",
                    "initial": "P.",
                    "last": "Willems"
                }
            ],
            "doi": "10.1016/j.vaccine.2009.07.076",
            "firstpage": "6504",
            "issn": "0264410X",
            "lastpage": "6511",
            "pmid": "19665608",
            "pub_year": 2009,
            "title": "A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra\u2122): Immunogenicity and safety profile",
            "volume": "27"
        },
        "b0120": {
            "authors": [
                {
                    "first": "Takao",
                    "initial": "T.",
                    "last": "Ozaki"
                },
                {
                    "first": "Naoko",
                    "initial": "N.",
                    "last": "Nishimura"
                },
                {
                    "first": "Yuji",
                    "initial": "Y.",
                    "last": "Kajita"
                }
            ],
            "doi": "10.1016/S0264-410X(00)00016-5",
            "firstpage": "2375",
            "issn": "0264410X",
            "lastpage": "2380",
            "pmid": "10738094",
            "pub_year": 2000,
            "title": "Experience with live attenuated varicella vaccine (Oka strain) in healthy Japanese subjects; 10-year survey at pediatric clinic",
            "volume": "18"
        },
        "b0125": {
            "authors": [
                {
                    "first": "P. H.",
                    "initial": "P.H.",
                    "last": "Dennehy"
                },
                {
                    "first": "K. S.",
                    "initial": "K.S.",
                    "last": "Reisinger"
                },
                {
                    "first": "M. M.",
                    "initial": "M.M.",
                    "last": "Blatter"
                },
                {
                    "first": "B. A.",
                    "initial": "B.A.",
                    "last": "Veloudis"
                }
            ],
            "firstpage": "604",
            "issn": "00314005",
            "lastpage": "607",
            "pmid": "1881743",
            "pub_year": 1991,
            "title": "Immunogenicity of subcutaneous versus intramuscular Oka/Merck varicella vaccination in healthy children",
            "volume": "88"
        },
        "b0130": {
            "authors": [
                {
                    "first": "Giuseppe",
                    "initial": "G.",
                    "last": "Ferrera"
                },
                {
                    "first": "Vincent",
                    "initial": "V.",
                    "last": "Gajdos"
                },
                {
                    "first": "St\u00e9phane",
                    "initial": "S.",
                    "last": "Thomas"
                },
                {
                    "first": "Cl\u00e9ment",
                    "initial": "C.",
                    "last": "Tran"
                },
                {
                    "first": "Anne",
                    "initial": "A.",
                    "last": "Figuet"
                }
            ],
            "doi": "10.4161/hv.8269",
            "firstpage": "455",
            "issn": "15548600",
            "lastpage": "460",
            "pmid": "19305145",
            "pub_year": 2009,
            "title": "Safety of a refrigerator-stable varicella vaccine (VARIVAX\u00ae) in healthy 12-to 15-month-old children - A randomized, double-blind, cross-over study",
            "volume": "5"
        }
    },
    "body_text": [
        {
            "endOffset": 30907,
            "parents": [],
            "secId": "s0065",
            "sentence": "A potential limitation of this study is that it was conducted in a single country; further studies might be needed to extrapolate these results to other populations.",
            "startOffset": 30742,
            "title": "Discussion"
        },
        {
            "endOffset": 15707,
            "parents": [],
            "secId": "s0005",
            "sentence": "A two-dose varicella (V) universal vaccination program has been implemented in selected Italian regions.",
            "startOffset": 15603,
            "title": "Introduction"
        },
        {
            "endOffset": 24835,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Within 4 days of vaccination, injection site redness was the most commonly reported solicited local symptom, with 29.8% subjects (MenC site) and 27.3% subjects (MMRV site) in the MMRV + MenC group, and with 23.2% subjects for the MMRV group (Fig. 2).",
            "startOffset": 24585,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 24316,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "GMCs and GMT in the MMRV + MenC group were generally similar to those in the MMRV group (Table 1).",
            "startOffset": 24218,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 28142,
            "parents": [],
            "refoffsets": {
                "b0045": {
                    "endOffset": 28141,
                    "startOffset": 28138
                }
            },
            "secId": "s0065",
            "sentence": "The immune responses to all vaccine antigens were high in all groups and were comparable to those observed by Vesikari et al. when combined MMRV + MenACWY was studied [9].",
            "startOffset": 27971,
            "title": "Discussion"
        },
        {
            "endOffset": 31634,
            "parents": [],
            "secId": "s0075",
            "sentence": "GSK Biologicals SA was involved in all stages of the study conduct and analysis, and took charge of all costs associated with developing and publishing the present manuscript.",
            "startOffset": 31459,
            "title": "Funding"
        },
        {
            "endOffset": 15774,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 15773,
                    "startOffset": 15770
                }
            },
            "secId": "s0005",
            "sentence": "First-dose vaccination uptake is around 51\u201384% by age 2 years [4].",
            "startOffset": 15708,
            "title": "Introduction"
        },
        {
            "endOffset": 21846,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "A sample size of 720 subjects was planned (MMRV + MenC: 360; MMRV: 180; MenC: 180), considering an approximately 10% non-inferiority margin for all antigens.",
            "startOffset": 21689,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 22260,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "The non-inferiority of MMRV + MenC versus MMRV vaccine alone was met if the lower limit (LL) of the standardized asymptotic 95% confidence intervals (CIs) for the post-vaccination difference in percentage of seroconverted subjects between the two groups (MMRV + MenC minus MMRV) was \u2a7e\u221210% for each vaccine antigen.",
            "startOffset": 21946,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 14967,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 14858,
                    "startOffset": 14855
                },
                "b0010": {
                    "endOffset": 14966,
                    "startOffset": 14963
                }
            },
            "secId": "s0005",
            "sentence": "In Italy, from 2011 to 2015, the annual number of reported measles cases fell from 5181 (8.5/100,000 population) [1] to 247 (0.4/100,000) [2], but notification rates are still higher than in many other European countries [2].",
            "startOffset": 14742,
            "title": "Introduction"
        },
        {
            "endOffset": 25873,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Very few subjects received prophylactic antipyretic medication: MMRV + MenC: 0.6%; MMRV: 0.5%; none for MenC.",
            "startOffset": 25764,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 28300,
            "parents": [],
            "refoffsets": {
                "b0075": {
                    "endOffset": 28299,
                    "startOffset": 28295
                }
            },
            "secId": "s0065",
            "sentence": "Similar results were seen in a study conducted in healthy children in the US where the MMRV vaccine was administered at the same time as other vaccines [15].",
            "startOffset": 28143,
            "title": "Discussion"
        },
        {
            "endOffset": 25222,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Grade 3 irritability/fussiness (crying that could not be comforted/prevented) was recorded in 8.9%, 7.3% and 4.1% of subjects, respectively.",
            "startOffset": 25082,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 16623,
            "parents": [],
            "secId": "s0005",
            "sentence": "However, information on the co-administration of MMRV and conjugate meningococcal vaccines is sparse.",
            "startOffset": 16522,
            "title": "Introduction"
        },
        {
            "endOffset": 24218,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "As the LL of the 95% CI for the MMRV + MenC minus MenC group difference was above \u221210%; non-inferiority was demonstrated (Table 1).",
            "startOffset": 24087,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 15603,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 15576,
                    "startOffset": 15573
                },
                "b0025": {
                    "endOffset": 15602,
                    "startOffset": 15599
                }
            },
            "secId": "s0005",
            "sentence": "However, Italian data from 2014 show MMR vaccine uptake levels of approximately 87% (first dose) [4] and 83% (second dose) [5].",
            "startOffset": 15476,
            "title": "Introduction"
        },
        {
            "endOffset": 21572,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Unsolicited symptoms (including SAEs) were defined as grade 3 if they prevented normal daily activity.",
            "startOffset": 21470,
            "title": "Safety/reactogenicity assessment"
        },
        {
            "endOffset": 29874,
            "parents": [],
            "refoffsets": {
                "b0110": {
                    "endOffset": 29873,
                    "startOffset": 29869
                }
            },
            "secId": "s0065",
            "sentence": "Further, a recent observational study carried out in the Veneto Region, in which over 10,000 forms were completed by mothers, showed that the overall rate of SAEs, including febrile convulsions, was no worse for MMRV as compared to MMR + V [22].",
            "startOffset": 29629,
            "title": "Discussion"
        },
        {
            "endOffset": 20383,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "For measles, mumps, rubella and varicella, subjects who were seropositive for each assay prior to vaccination did not contribute to the seroconversion rate or geometric mean concentration (GMC) calculations.",
            "startOffset": 20176,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 32490,
            "parents": [],
            "secId": "s0085",
            "sentence": "MC reports personal fees and non-financial support from GSK group of companies during the conduct of the study.",
            "startOffset": 32379,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 30640,
            "parents": [],
            "secId": "s0065",
            "sentence": "Unsurprisingly, rash (any) was higher in the subjects who received MMRV vaccine as compared to MenC vaccine in our study.",
            "startOffset": 30519,
            "title": "Discussion"
        },
        {
            "endOffset": 17406,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Open phase IIIb, randomized, study conducted at 13 centers in Italy between February 2012 and March 2014.",
            "startOffset": 17301,
            "title": "Study design and subjects"
        },
        {
            "endOffset": 21078,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "The intensity of all symptoms was graded on a scale of 0\u20133; where \u201cGrade 0\u201d was none/as usual, \u201cGrade 1\u201d was mild, \u201cGrade 2\u201d was moderate and \u201cGrade 3\u201d was severe.",
            "startOffset": 20915,
            "title": "Safety/reactogenicity assessment"
        },
        {
            "endOffset": 23782,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "In the group which received MMRV alone, the MMRV seroconversion rates were 99.4%, 93.2%, 100% and 100%, respectively (Table 1).",
            "startOffset": 23655,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 25489,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "MMRV-specific solicited general symptoms reported during the 43-day post-vaccination period included parotid gland swelling in 0.9% (MMRV + MenC group), 2.3% (MMRV group); and meningism/febrile convulsion in 0.3% (MMRV + MenC group) and 0.6% (MenC group) of subjects.",
            "startOffset": 25222,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 28525,
            "parents": [],
            "refoffsets": {
                "b0080": {
                    "endOffset": 28524,
                    "startOffset": 28517
                },
                "b0085": {
                    "endOffset": 28524,
                    "startOffset": 28517
                }
            },
            "secId": "s0065",
            "sentence": "The expected peak in fever within 5\u201312 days after MMRV dosing in our study is comparable with previous reports [16,17].",
            "startOffset": 28406,
            "title": "Discussion"
        },
        {
            "endOffset": 32611,
            "parents": [],
            "secId": "s0085",
            "sentence": "GG received payment from the GSK group of companies through his previous institution for conducting this clinical trial.",
            "startOffset": 32491,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 17839,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Healthy male or female subjects, aged 13\u201315 months, were randomized (2:1:1) to receive either single doses of MMRV and MenC vaccines administered concomitantly as separate injections on the same day (MMRV + MenC Group); a single dose of MMRV at one visit followed 42 days later by a single dose of MenC vaccine (MMRV Group); or a single dose of MenC at one visit followed 42 days later by a single dose of MMRV vaccine (MenC Group).",
            "startOffset": 17407,
            "title": "Study design and subjects"
        },
        {
            "endOffset": 18554,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Independent ethics committees and/or institutional review boards at each participating center reviewed and approved all study-related documents.",
            "startOffset": 18410,
            "title": "Study design and subjects"
        },
        {
            "endOffset": 28922,
            "parents": [],
            "secId": "s0065",
            "sentence": "It is worth nothing that the MMRV fever pattern was not modified by co-administration of mono- or tetravalent-conjugated meningococcal vaccines.",
            "startOffset": 28778,
            "title": "Discussion"
        },
        {
            "endOffset": 31954,
            "parents": [],
            "secId": "s0080",
            "sentence": "All provided substantial intellectual and scientific input during manuscript development, critically reviewing the content, revising the manuscript and giving final approval before submission.",
            "startOffset": 31762,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 30387,
            "parents": [],
            "refoffsets": {
                "b0115": {
                    "endOffset": 30386,
                    "startOffset": 30382
                }
            },
            "secId": "s0065",
            "sentence": "It has been reported that GMC values for measles are higher following MMRV vaccine administration as compared to MMR + V [23].",
            "startOffset": 30261,
            "title": "Discussion"
        },
        {
            "endOffset": 27115,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "There were no deaths during the study.",
            "startOffset": 27077,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 26385,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Rash was observed in 27.0% of MMRV + MenC subjects, 23.2% in the MMRV group and 8.8% in the MenC group.",
            "startOffset": 26282,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 26998,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "SAEs were reported in 12 subjects (MMRV + MenC: 6; MMRV: 4; MenC: 2).",
            "startOffset": 26929,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 32378,
            "parents": [],
            "secId": "s0085",
            "sentence": "PD received payments from the GSK group of companies, Crucell Berna, SanofiPasteur MSD, Pfizer and Novartis.",
            "startOffset": 32270,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 23488,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "The study population was predominantly Caucasian (81.3%).",
            "startOffset": 23431,
            "title": "Demographics"
        },
        {
            "endOffset": 25763,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "The characteristic peak in fever at 5\u201312 days post MMRV vaccination was observed in the MMRV + MenC and MMRV groups (Fig. 4).",
            "startOffset": 25638,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 29628,
            "parents": [],
            "refoffsets": {
                "b0090": {
                    "endOffset": 29476,
                    "startOffset": 29472
                },
                "b0105": {
                    "endOffset": 29627,
                    "startOffset": 29623
                }
            },
            "secId": "s0065",
            "sentence": "The rate of febrile convulsions observed in Germany for Priorix-Tetra (2.18/10,000 vaccinees) [18] is consistent with the range (0.87/10,000\u20133.37/10,000) recorded by the Veneto region vaccine surveillance system (Canale Verde) from 2008 to 2014 [21].",
            "startOffset": 29378,
            "title": "Discussion"
        },
        {
            "endOffset": 30016,
            "parents": [],
            "secId": "s0065",
            "sentence": "Although not statistically powered, the rate of febrile convulsion was comparable for both strategies [risk ratio (95% CI) 0.80 (0.30\u20132.15)].",
            "startOffset": 29875,
            "title": "Discussion"
        },
        {
            "endOffset": 30162,
            "parents": [],
            "refoffsets": {
                "b0110": {
                    "endOffset": 30161,
                    "startOffset": 30157
                }
            },
            "secId": "s0065",
            "sentence": "The Veneto study also showed that mothers of toddlers who received MMR + V rather than MMRV had higher levels of stress and risk perception [22].",
            "startOffset": 30017,
            "title": "Discussion"
        },
        {
            "endOffset": 20915,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Unsolicited symptoms were recorded for 43 days after each dose and serious adverse events (SAEs) were recorded throughout the study.",
            "startOffset": 20783,
            "title": "Safety/reactogenicity assessment"
        },
        {
            "endOffset": 30260,
            "parents": [],
            "secId": "s0065",
            "sentence": "Measles seroconversion was high in both MMRV and MMRV + MenC groups and GMCs were also unaffected.",
            "startOffset": 30162,
            "title": "Discussion"
        },
        {
            "endOffset": 20783,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Parents/guardians used diary cards to record solicited injection site symptoms for 4 days after each vaccine and solicited general symptoms for 43 days post-MMRV vaccination (fever, rash/exanthema, parotid/salivary gland swelling, signs of meningism, febrile convulsions) and for 15 days post-MenC vaccination (drowsiness, irritability/fussiness, loss of appetite).",
            "startOffset": 20418,
            "title": "Safety/reactogenicity assessment"
        },
        {
            "endOffset": 26169,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "The second occurred 28 days after vaccination, was a grade 3 SAE, but was considered not related to vaccination.",
            "startOffset": 26057,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 22469,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Similarly, for MMRV + MenC versus MenC vaccine, the post-vaccination difference in the percentages of seroprotected subjects between the two groups (MMRV + MenC minus MenC) was \u2a7e\u221210% for rSBA-MenC antibodies.",
            "startOffset": 22261,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 19425,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "A single 0.5 mL dose of MMRV vaccine (Priorix-Tetra\u2122, GSK, Belgium; batch numbers: AD01B698A, AD01C132D, AD01B538B, A71CA677A, AMRVA138A, AMRVA200B, and AMRVA162B; comprising a lyophilized cake which was reconstituted with the diluent from a pre-filled syringe before administration) was administered subcutaneously in the deltoid region of the upper arm.",
            "startOffset": 19070,
            "title": "Study vaccines"
        },
        {
            "endOffset": 19606,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "A single 0.5 mL dose of MenC CRM-197 conjugated vaccine (Meningitec, Nuron Biotech; batch numbers: F32046, F15126 and G26516) was administered intramuscularly into the upper thigh.",
            "startOffset": 19426,
            "title": "Study vaccines"
        },
        {
            "endOffset": 23312,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Of 716 enrolled subjects (MMRV + MenC: 351; MMRV: 183; MenC: 182), 626 were included in the ATP cohort for immunogenicity (MMRV + MenC: 315; MMRV: 168; MenC: 143; Fig. 1).",
            "startOffset": 23141,
            "title": "Demographics"
        },
        {
            "endOffset": 25945,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Only two subjects in the MMRV + MenC group reported febrile convulsions.",
            "startOffset": 25873,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 16018,
            "parents": [],
            "refoffsets": {
                "b0020": {
                    "endOffset": 16017,
                    "startOffset": 16014
                }
            },
            "secId": "s0005",
            "sentence": "Conjugated meningitis C (MenC) vaccine uptake in the second year of life is also suboptimal in Italy, at approximately 75% [4].",
            "startOffset": 15891,
            "title": "Introduction"
        },
        {
            "endOffset": 16818,
            "parents": [],
            "refoffsets": {
                "b0045": {
                    "endOffset": 16797,
                    "startOffset": 16794
                },
                "b0050": {
                    "endOffset": 16817,
                    "startOffset": 16813
                }
            },
            "secId": "s0005",
            "sentence": "To date, only two studies have examined the co-administration of MMRV with vaccines against MenC: either meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) [9] or MenACWY-CRM [10].",
            "startOffset": 16624,
            "title": "Introduction"
        },
        {
            "endOffset": 18409,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The study adhered to Good Clinical Practice, the Declaration of Helsinki, and local Italian rules and regulations.",
            "startOffset": 18295,
            "title": "Study design and subjects"
        },
        {
            "endOffset": 31029,
            "parents": [],
            "secId": "s0065",
            "sentence": "In conclusion, the co-administration of the MMRV vaccine with MenC was immunogenic and well tolerated in Italian toddlers.",
            "startOffset": 30907,
            "title": "Discussion"
        },
        {
            "endOffset": 15350,
            "parents": [],
            "refoffsets": {
                "b0015": {
                    "endOffset": 15349,
                    "startOffset": 15346
                }
            },
            "secId": "s0005",
            "sentence": "Data from 2010 to 2011 showed that, in Italy, the vast majority (96%) of measles cases were in people who were either unvaccinated or incompletely vaccinated; and that adolescents and young adults were most affected (i.e. those that did not receive childhood measles-mumps-rubella (MMR) vaccination as part of the national immunization program, as it was only included in 1999) [3].",
            "startOffset": 14968,
            "title": "Introduction"
        },
        {
            "endOffset": 26282,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Rather, the investigator thought that it was caused by a viral infection, as blood analyses showed leukocytosis.",
            "startOffset": 26170,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 33046,
            "parents": [],
            "secId": "s0085",
            "sentence": "GG acted as investigator in clinical trials for the GSK group of companies, Sanofi Pasteur MSD and Novartis, has received fees from the GSK group of companies, Sanofi Pasteur MSD and Sequirus for board membership, consulting fees from the GSK group of companies as well as payment for lectures from the GSK group of companies, Sanofi Pasteur MSD, Novartis, Crucell/Janssen, Pfizer and payment for manuscript preparation from Novartis.",
            "startOffset": 32612,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 30742,
            "parents": [],
            "secId": "s0065",
            "sentence": "Most other adverse events were generally mild-to-moderate; and no vaccine-related SAEs were reported.",
            "startOffset": 30641,
            "title": "Discussion"
        },
        {
            "endOffset": 31297,
            "parents": [],
            "secId": "s0070",
            "sentence": "Priorix-Tetra\u2122 is a registered trademark of the GSK group of companies.",
            "startOffset": 31226,
            "title": "Trademark statement"
        },
        {
            "endOffset": 19704,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0025",
            "sentence": "The needle sets provided for MMRV and MenC vaccines were 8 mm 25G5 and 1.25 mm 25G, respectively.",
            "startOffset": 19607,
            "title": "Study vaccines"
        },
        {
            "endOffset": 18670,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Parents/guardians of subjects provided written informed consent before any study-related procedures were performed.",
            "startOffset": 18555,
            "title": "Study design and subjects"
        },
        {
            "endOffset": 17251,
            "parents": [],
            "secId": "s0005",
            "sentence": "This non-inferiority study was therefore undertaken to compare the immunogenicity and safety of co- and separate administration of MMRV and MenC vaccines in healthy Italian toddlers.",
            "startOffset": 17069,
            "title": "Introduction"
        },
        {
            "endOffset": 19798,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Blood samples were collected before and 43 days after vaccination.",
            "startOffset": 19732,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 26602,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Grade 3 rash (>150 lesions) was reported in \u2a7d0.6% subjects.",
            "startOffset": 26543,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 31347,
            "parents": [],
            "secId": "s0070",
            "sentence": "Meningitec\u2122 is a trademark of Nuron Biotech BV, US",
            "startOffset": 31297,
            "title": "Trademark statement"
        },
        {
            "endOffset": 24086,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "At 42 days post-vaccination, the seroprotection rate for rSBA-MenC in the MMRV + MenC group was 98.3% compared with 99.3% in the subjects who received MenC alone (Table 1).",
            "startOffset": 23914,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 26056,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "The first occurred 8 days after vaccination, was considered related to vaccination, but was of mild intensity.",
            "startOffset": 25946,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 17068,
            "parents": [],
            "secId": "s0005",
            "sentence": "The aim of the study reported here was to provide data on the co-administration of MMRV and MenC in Italy.",
            "startOffset": 16962,
            "title": "Introduction"
        },
        {
            "endOffset": 25637,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "The percentages of subjects who developed fever during the 43-day post-vaccination period were: 64.9% (MMRV + MenC), 64.4% (MMRV) and 37.4% (MenC).",
            "startOffset": 25490,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 32198,
            "parents": [],
            "secId": "s0085",
            "sentence": "OH, MP and FM are employees of the GSK group of companies.",
            "startOffset": 32140,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 26929,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "The most common symptoms were: pharyngitis in the MMRV + MenC and MenC subjects (n = 16 [4.6%] and n = 9 [4.9%], respectively) and cough, pharyngitis and diarrhea (n = 10; 5.5% for each symptom) in the MMRV group.",
            "startOffset": 26716,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 30518,
            "parents": [],
            "refoffsets": {
                "b0120": {
                    "endOffset": 30517,
                    "startOffset": 30510
                },
                "b0125": {
                    "endOffset": 30517,
                    "startOffset": 30510
                },
                "b0130": {
                    "endOffset": 30517,
                    "startOffset": 30510
                }
            },
            "secId": "s0065",
            "sentence": "Rash is a common adverse event following the administration of varicella vaccine, affecting between 3% and 17% of subjects [24\u201326].",
            "startOffset": 30387,
            "title": "Discussion"
        },
        {
            "endOffset": 31458,
            "parents": [],
            "secId": "s0075",
            "sentence": "This study (NCT01506193) was sponsored and funded by GlaxoSmithKline Biologicals SA, Rixensart, Belgium.",
            "startOffset": 31354,
            "title": "Funding"
        },
        {
            "endOffset": 20175,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Anti-meningococcal serogroup activity (rSBA-MenC) was measured using an in-house serum bactericidal test (cut-off: \u2a7e1:8).",
            "startOffset": 20054,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 21469,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Grade 3 solicited symptoms were defined as: pain: cried when limb was moved or a spontaneously painful limb; redness and swelling: injection site surface diameter >20 mm; fever: rectal temperature >39.5 \u00b0C; rash: >150 lesions; irritability/fussiness: crying that cannot be comforted/prevented normal activity; drowsiness: which prevents normal activity; loss of appetite: not eating at all.",
            "startOffset": 21079,
            "title": "Safety/reactogenicity assessment"
        },
        {
            "endOffset": 29377,
            "parents": [],
            "secId": "s0065",
            "sentence": "One occurred on day 8, was mild in intensity, and was considered related to vaccination; the other occurred on day 28, was a grade 3 SAE, but was not considered to be related to the vaccine.",
            "startOffset": 29187,
            "title": "Discussion"
        },
        {
            "endOffset": 27076,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "None were causally related to vaccination and no subject withdrew due to SAE.",
            "startOffset": 26999,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 16205,
            "parents": [],
            "refoffsets": {
                "b0035": {
                    "endOffset": 16099,
                    "startOffset": 16096
                }
            },
            "secId": "s0005",
            "sentence": "As a maximum of two vaccine injections per visit is considered ideal in Italy [7], a potential tool to increase vaccine uptake is to use combination vaccines along with co-administration.",
            "startOffset": 16018,
            "title": "Introduction"
        },
        {
            "endOffset": 18940,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The co-primary objectives of the study were to show the non-inferiority of: co-administering MMRV vaccine with MenC conjugate vaccine compared to MMRV vaccine alone; and co-administering MenC vaccine with MMRV compared to MenC conjugate vaccine alone.",
            "startOffset": 18689,
            "title": "Study objectives"
        },
        {
            "endOffset": 20053,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Antibody titers against MMRV were measured using commercial enzyme-linked immunosorbent assays (ELISA) \u2013 (Enzygnos Dade Behring, Marburg, Germany) with cut-off values of 150 mIU/mL (measles), 231 U/mL (mumps), 4 IU/mL (rubella) and 25 mIU/mL (varicella).",
            "startOffset": 19799,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 31207,
            "parents": [],
            "secId": "s0065",
            "sentence": "Such co-administration in routine clinical practice would reduce the number of required clinic visits and has the potential to improve vaccine acceptance, compliance and uptake.",
            "startOffset": 31030,
            "title": "Discussion"
        },
        {
            "endOffset": 31761,
            "parents": [],
            "secId": "s0080",
            "sentence": "All named authors have contributed in the design/acquisition of data or analysis and data interpretation.",
            "startOffset": 31656,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 15890,
            "parents": [],
            "refoffsets": {
                "b0030": {
                    "endOffset": 15889,
                    "startOffset": 15886
                }
            },
            "secId": "s0005",
            "sentence": "However, uptake was lower in regions where MMR + V was used rather than measles-mumps-rubella-varicella (MMRV) [6].",
            "startOffset": 15775,
            "title": "Introduction"
        },
        {
            "endOffset": 28405,
            "parents": [],
            "secId": "s0065",
            "sentence": "The study vaccines were generally well tolerated and clinically acceptable safety profiles were observed.",
            "startOffset": 28300,
            "title": "Discussion"
        },
        {
            "endOffset": 26715,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "At least one unsolicited symptom was reported for 27.6% (MMRV + MenC), 33.3% (MMRV) and 22.5% (MenC) of subjects.",
            "startOffset": 26602,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 33101,
            "parents": [],
            "secId": "s0085",
            "sentence": "SE, GB MGD, GF, AP, FS report no conflict of interest.",
            "startOffset": 33047,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 18295,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Subjects were excluded if they had: received any investigational drug/vaccine 30 days before the study vaccine or immunosuppressive medication/immunoglobulins/blood products for \u2a7e14 days within 6 months; major congenital defects; chronic illness or a family history of immunodeficiency; human immunodeficiency virus; symptoms of acute illness or fever; previous vaccination/history/known exposure to MMRV and/or Neisseria meningitidis serogroup C diseases.",
            "startOffset": 17839,
            "title": "Study design and subjects"
        },
        {
            "endOffset": 23654,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "At 42 days post-vaccination, the seroconversion rates for the MMRV antigens in the MMRV + MenC group were 99.3%, 94.5%, 100% and 99.7%, respectively.",
            "startOffset": 23505,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 16521,
            "parents": [],
            "secId": "s0005",
            "sentence": "Thus, co-administration of MMRV plus a meningococcal conjugate vaccine at one visit might be beneficial.",
            "startOffset": 16417,
            "title": "Introduction"
        },
        {
            "endOffset": 19053,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Secondary objectives included the 42-day post-vaccination immunogenicity and tolerability of each study vaccine.",
            "startOffset": 18941,
            "title": "Study objectives"
        },
        {
            "endOffset": 23430,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "The overall mean age was 13.4 \u00b1 0.6 months and 53.7% were male.",
            "startOffset": 23367,
            "title": "Demographics"
        },
        {
            "endOffset": 25081,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Irritability/fussiness was the most frequently reported solicited general symptom during the 15-day post-vaccination period and was experienced by 55.7%, 58.8% and 49.1% of subjects in the MMRV + MenC, MMRV and MenC groups, respectively (Fig. 3).",
            "startOffset": 24835,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 32120,
            "parents": [],
            "secId": "s0080",
            "sentence": "The work described was carried out in accordance with the ICMJE recommendations for conducting, reporting, editing and publishing scholarly work in medical journals.",
            "startOffset": 31955,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 23118,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "The safety analysis was performed on the total vaccinated cohort (TVC) which included all vaccinated subjects.",
            "startOffset": 23008,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 22731,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "The immunogenicity analysis was performed on the according-to-protocol (ATP) cohort, which included all subjects with available pre- and post-vaccination serology results, who were seronegative for at least one vaccine antigen and complied with study procedures.",
            "startOffset": 22469,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 27780,
            "parents": [],
            "secId": "s0065",
            "sentence": "However, this is the first study comparing the immunogenicity and safety of co-administered MMRV + MenC vaccines in healthy Italian children.",
            "startOffset": 27639,
            "title": "Discussion"
        },
        {
            "endOffset": 28777,
            "parents": [],
            "refoffsets": {
                "b0045": {
                    "endOffset": 28776,
                    "startOffset": 28773
                }
            },
            "secId": "s0065",
            "sentence": "Similar observations were reported by Vesikari et al. when ACWY-TT + MMRV and MMRV alone vaccines were given to children aged 12\u201323 months [9].",
            "startOffset": 28634,
            "title": "Discussion"
        },
        {
            "endOffset": 21689,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "All statistical analyses were performed using Statistical Analysis Software (SAS) version 9.2.",
            "startOffset": 21595,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 23008,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Seroconversion rates (antibody concentration/titer \u2a7ecut-off value in initially seronegative subjects), seroprotection rates (rSBA-MenC antibody titer \u2a7e1:8), GMCs and geometric mean titers (GMTs) against each vaccine antigen were calculated with 95% CIs (cut-offs given above).",
            "startOffset": 22732,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 29186,
            "parents": [],
            "refoffsets": {
                "b0090": {
                    "endOffset": 28949,
                    "startOffset": 28945
                },
                "b0095": {
                    "endOffset": 29113,
                    "startOffset": 29106
                },
                "b0100": {
                    "endOffset": 29113,
                    "startOffset": 29106
                }
            },
            "secId": "s0065",
            "sentence": "Although Schink et al. [18] showed a relationship between MMRV and febrile convulsion, and other studies have shown an increased risk of febrile convulsions with combined MMRV vaccine [19,20], two subjects in our MMRV + MenC group experienced a febrile convulsion.",
            "startOffset": 28922,
            "title": "Discussion"
        },
        {
            "endOffset": 16416,
            "parents": [],
            "refoffsets": {
                "b0040": {
                    "endOffset": 16415,
                    "startOffset": 16412
                }
            },
            "secId": "s0005",
            "sentence": "The current Italian vaccination recommendations for children aged 13 months include: (1) MMRV or MMR + V; (2) MenC or conjugated meningococcal ACWY (MenACWY) vaccine; and (3) meningococcal B (MenB) vaccine [8].",
            "startOffset": 16206,
            "title": "Introduction"
        },
        {
            "endOffset": 32269,
            "parents": [],
            "secId": "s0085",
            "sentence": "OH reports ownership of stock options from the GSK group of companies.",
            "startOffset": 32199,
            "title": "Conflict of interest"
        },
        {
            "endOffset": 16962,
            "parents": [],
            "refoffsets": {
                "b0045": {
                    "endOffset": 16961,
                    "startOffset": 16955
                },
                "b0050": {
                    "endOffset": 16961,
                    "startOffset": 16955
                }
            },
            "secId": "s0005",
            "sentence": "Both studies found that the vaccines could be co-administered without affecting the immunogenicity or safety profiles of either vaccine [9,10].",
            "startOffset": 16819,
            "title": "Introduction"
        },
        {
            "endOffset": 27638,
            "parents": [],
            "refoffsets": {
                "b0045": {
                    "endOffset": 27236,
                    "startOffset": 27233
                },
                "b0050": {
                    "endOffset": 27254,
                    "startOffset": 27250
                },
                "b0055": {
                    "endOffset": 27391,
                    "startOffset": 27387
                },
                "b0060": {
                    "endOffset": 27494,
                    "startOffset": 27490
                },
                "b0065": {
                    "endOffset": 27507,
                    "startOffset": 27503
                },
                "b0070": {
                    "endOffset": 27637,
                    "startOffset": 27633
                }
            },
            "secId": "s0065",
            "sentence": "Several trials have already shown the feasibility of co-administering MMRV with other vaccines: MenACWY-TT [9], MenACWY-CRM [10], reduced-antigen content diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine (dTpa-IPV) or full-strength DTPa-IPV [11], 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) [12], 4CMenB [13], or H. influenzae type b conjugate-hepatitis B vaccine (Hib/HepB) and diphtheria-tetanus-acellular pertussis vaccines (DTaP) [14].",
            "startOffset": 27126,
            "title": "Discussion"
        },
        {
            "endOffset": 23366,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "The baseline demography did not differ by study group.",
            "startOffset": 23312,
            "title": "Demographics"
        },
        {
            "endOffset": 26542,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Varicella-like rash was observed in 1.8%, 0.6% and 0.6% subjects, respectively and measles/rubella-like rash was seen in 11.9%, 9.0% and 1.2%, respectively.",
            "startOffset": 26386,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 15475,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 15474,
                    "startOffset": 15471
                }
            },
            "secId": "s0005",
            "sentence": "The uptake for MMR is particularly concerning, as \u2a7e95% uptake is necessary to interrupt endemic transmission of measles [2].",
            "startOffset": 15351,
            "title": "Introduction"
        },
        {
            "endOffset": 24557,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "However, it should be noted that no statistical analysis of these comparisons was planned in the study protocol, and no predefined non-inferiority criteria were set, so eventual comparison of these groups should be interpreted with caution.",
            "startOffset": 24317,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 27971,
            "parents": [],
            "secId": "s0065",
            "sentence": "The results show that the immune responses to MMRV and rSBA antibodies were non-inferior after the combined administration compared with those elicited by either MMRV or MenC vaccines alone.",
            "startOffset": 27781,
            "title": "Discussion"
        },
        {
            "endOffset": 28633,
            "parents": [],
            "secId": "s0065",
            "sentence": "The pattern of fever was comparable between the MMRV + MenC and MMRV groups and higher than the MenC group.",
            "startOffset": 28526,
            "title": "Discussion"
        },
        {
            "endOffset": 23914,
            "parents": [
                {
                    "id": "s0045",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "As the LL of the 95% CI for the MMRV + MenC minus MMRV group difference was above \u221210%; non-inferiority was demonstrated (Table 1).",
            "startOffset": 23783,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 21946,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Materials and methods"
                }
            ],
            "secId": "s0040",
            "sentence": "The 2:1:1 blocking randomization scheme ensured that the balance between treatments was maintained.",
            "startOffset": 21847,
            "title": "Statistical analysis"
        }
    ],
    "docId": "S0264410X16305825",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": "durando@unige.it",
                "first": "Paolo",
                "initial": "P.",
                "last": "Durando"
            },
            {
                "email": "susanna.esposito@unimi.it",
                "first": "Susanna",
                "initial": "S.",
                "last": "Esposito"
            },
            {
                "email": "gianni.bona@maggioreosp.novara.it",
                "first": "Gianni",
                "initial": "G.",
                "last": "Bona"
            },
            {
                "email": "mario.cuccia@aspct.it",
                "first": "Mario",
                "initial": "M.",
                "last": "Cuccia"
            },
            {
                "email": "madesole@aslsassari.it",
                "first": "Maria Giuseppina",
                "initial": "M.G.",
                "last": "Desole"
            },
            {
                "email": "servizio.epidemiologia@asp.rg.it",
                "first": "Giuseppe",
                "initial": "G.",
                "last": "Ferrera"
            },
            {
                "email": "giovanni.gabutti@unife.it",
                "first": "Giovanni",
                "initial": "G.",
                "last": "Gabutti"
            },
            {
                "email": "angelo.pellegrino@aslcn1.it",
                "first": "Angelo",
                "initial": "A.",
                "last": "Pellegrino"
            },
            {
                "email": "filippo.salvini@asst-santipaolocarlo.it",
                "first": "Filippo",
                "initial": "F.",
                "last": "Salvini"
            },
            {
                "email": "ouzama.n.henry@gsk.com",
                "first": "Ouzama",
                "initial": "O.",
                "last": "Henry"
            },
            {
                "email": "michael.x.povey@gsk.com",
                "first": "Michael",
                "initial": "M.",
                "last": "Povey"
            },
            {
                "email": "federico.e.marchetti@gsk.com",
                "first": "Federico",
                "initial": "F.",
                "last": "Marchetti"
            }
        ],
        "doi": "10.1016/j.vaccine.2016.07.009",
        "firstpage": "4278",
        "issn": "0264410X",
        "keywords": [
            "Conjugated meningococcal C vaccine",
            "Immunogenicity",
            "Italy",
            "Measles-mumps-rubella-varicella vaccine",
            "Safety",
            "Vaccination schedule"
        ],
        "lastpage": "4284",
        "openaccess": "Full",
        "pub_year": 2016,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "The immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine when co-administered with conjugated meningococcal C vaccine to healthy children: A phase IIIb, randomized, multi-center study in Italy"
    }
}